Survival benefit of autologous transplant (ASCT) for mantle cell lymphoma (MCL) in the California Cancer Registry (CCR).doi:10.1200/JCO.2024.42.16_suppl.e190436422e19043#Background:Extended follow up of the prospective Nordic MCL2 cohort shows ASCT in CR1 confers a median OS (mOS) of 12.7...
What is the survival rate of metastatic breast cancer? What is the survival rate for non-Hodgkin lymphoma? What is the survival rate for bone marrow cancer? How is medullary thyroid cancer diagnosed? What is the survival rate of spinal cancer?
Hong Koo Ha, Min Chul Cho, in Bladder Cancer, 2018 Conclusion While cancer-specific survival rate was in favor of patients who undergo early RC for high-risk NMIBC, significant proportion of patients still would be overtreated. In addition, the potential morbidity and mortality of the ...
Population-based information about cancer occurrence and survival are required to inform clinical practice and research; but for most lymphomas data are lacking. Set within a socio-demographically representative UK population of nearly 4 million, lymphom
The antitumor potential of the rhizome whole ethanol extract, tested in MCF-7 breast cancer cells, furnished inhibition of note in cell proliferation (<50% cell survival rate) but only at relatively high concentration (75 μg/mL) [295]. At the same time, the extract elicited DNA ...
Non-Hodgkin's lymphoma (NHL) is cancer of the lymphatic system, a vital part of the body's immune system. Symptoms include swollen lymph nodes, fever, night sweats, coughing, weakness, chest pain, unexplained weight loss, and abdominal pain. Non-Hodgkin's lymphoma is a type of cancer th...
fear of cancer recurrencelymphomasurvivalObjective: This study aimed to evaluate FCR among lymphoma patients who completed treatment and its impact on survival and quality of life (QOL). Methods: In this prospective cohort study, 467 lymphoma patients were included who completed treatment with curative...
Patients with refractory large B-cell lymphoma who were treated with axicabtagene ciloleucel (axi-cel; Yescarta) had a 3-year overall survival (OS) rate of 47%, according to an updated analysis of the phase II ZUMA-1 trial. The median duration of follow-up was...
Phase I/II study of daily carboplatin, 5-fluorouracil and concurrent radiation therapy for locally advanced non-small-cell lung cancer A study was undertaken to determine the maximum tolerated dose, the dose-limiting toxicities and the response rate of carboplatin and 5-fluorouracil admini... H, ...
Different progression-free survival rates may be given for different populations, such as men, women, children, seniors, ethnic groups, and groups with comorbid conditions (such asdiabeteswithlymphoma). What It Doesn’t Tell You Being progression-free doesn’t mean that the cancer has been cured...